EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Omeros Lines Up $40M Financing

Omeros (NASDAQ: OMER), the Seattle-based biotech company, has struck a deal in which it may raise as much as $40 million over the next two years through selling shares of common stock to a single investor, Azimuth Opportunity. Omeros raised $68.2 million through its initial public offering in October, but securing more money at certain times should help strengthen its bargaining position “as we pursue strategic opportunities,” the company said in a statement.